Superior Vena Cava Resection for Lung and Mediastinal Malignancies: A Single-Center Experience With 70 Cases

Lorenzo Spaggiari, Francesco Leo, Giulia Veronesi, Piergiorgio Solli, Domenico Galetta, Brunilda Tatani, Francesco Petrella, Davide Radice

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Background: The oncologic value of superior vena cava (SVC) resection for lung and mediastinal malignancies remains controversial. In this context, we have reviewed our experience in the treatment of locally advanced lung and mediastinal tumor invading the SVC system, analyzing postoperative outcome and long-term oncologic results. Methods: The clinical data of patients who underwent SVC resection were retrospectively analyzed to assess postoperative mortality, and overall and procedure-specific morbidity. Overall survival was calculated for mediastinal and lung tumor groups. Results: From 1998 to 2004, 70 consecutive patients (52 with lung cancer and 18 with mediastinal tumors) underwent SVC system resection. There were 25 replacements (36%) of the SVC system by prosthesis, whereas the remaining underwent partial resection. Major postoperative morbidity and mortality rates in lung cancer patients were 23% and 7.7%, respectively (50% and 5.6% in mediastinal tumors). In the lung cancer group, 5-year survival probability was 31%, and it was affected by mediastinal nodal status (5-year survival in N0-N1 patients 52%, 21% in N2 patients, 0 in N3 patients). Median survival for mediastinal tumors was 49 months. Conclusions: In conclusion, SVC resection may achieve permanent cure in patients who would have been defined as inoperable 10 years ago. In the case of mediastinal tumors, the need for SVC resection alone should not be considered a contraindication for surgery when prosthetic replacement is feasible. In the case of lung tumors, infiltration of SVC can achieve satisfactory long-term results after neoadjuvant chemotherapy, only when pathologic N2 disease is excluded by preoperative mediastinoscopy.

Original languageEnglish
Pages (from-to)223-230
Number of pages8
JournalAnnals of Thoracic Surgery
Volume83
Issue number1
DOIs
Publication statusPublished - Jan 2007

Fingerprint

Superior Vena Cava
Lung
Neoplasms
Lung Neoplasms
Survival
Mediastinoscopy
Morbidity
Mortality
Prostheses and Implants
Drug Therapy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Superior Vena Cava Resection for Lung and Mediastinal Malignancies : A Single-Center Experience With 70 Cases. / Spaggiari, Lorenzo; Leo, Francesco; Veronesi, Giulia; Solli, Piergiorgio; Galetta, Domenico; Tatani, Brunilda; Petrella, Francesco; Radice, Davide.

In: Annals of Thoracic Surgery, Vol. 83, No. 1, 01.2007, p. 223-230.

Research output: Contribution to journalArticle

@article{4725c141b32241a3a06c6e2a2cc1e86f,
title = "Superior Vena Cava Resection for Lung and Mediastinal Malignancies: A Single-Center Experience With 70 Cases",
abstract = "Background: The oncologic value of superior vena cava (SVC) resection for lung and mediastinal malignancies remains controversial. In this context, we have reviewed our experience in the treatment of locally advanced lung and mediastinal tumor invading the SVC system, analyzing postoperative outcome and long-term oncologic results. Methods: The clinical data of patients who underwent SVC resection were retrospectively analyzed to assess postoperative mortality, and overall and procedure-specific morbidity. Overall survival was calculated for mediastinal and lung tumor groups. Results: From 1998 to 2004, 70 consecutive patients (52 with lung cancer and 18 with mediastinal tumors) underwent SVC system resection. There were 25 replacements (36{\%}) of the SVC system by prosthesis, whereas the remaining underwent partial resection. Major postoperative morbidity and mortality rates in lung cancer patients were 23{\%} and 7.7{\%}, respectively (50{\%} and 5.6{\%} in mediastinal tumors). In the lung cancer group, 5-year survival probability was 31{\%}, and it was affected by mediastinal nodal status (5-year survival in N0-N1 patients 52{\%}, 21{\%} in N2 patients, 0 in N3 patients). Median survival for mediastinal tumors was 49 months. Conclusions: In conclusion, SVC resection may achieve permanent cure in patients who would have been defined as inoperable 10 years ago. In the case of mediastinal tumors, the need for SVC resection alone should not be considered a contraindication for surgery when prosthetic replacement is feasible. In the case of lung tumors, infiltration of SVC can achieve satisfactory long-term results after neoadjuvant chemotherapy, only when pathologic N2 disease is excluded by preoperative mediastinoscopy.",
author = "Lorenzo Spaggiari and Francesco Leo and Giulia Veronesi and Piergiorgio Solli and Domenico Galetta and Brunilda Tatani and Francesco Petrella and Davide Radice",
year = "2007",
month = "1",
doi = "10.1016/j.athoracsur.2006.07.075",
language = "English",
volume = "83",
pages = "223--230",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "The Society of Thoracic Surgeons. Published by Elsevier Inc",
number = "1",

}

TY - JOUR

T1 - Superior Vena Cava Resection for Lung and Mediastinal Malignancies

T2 - A Single-Center Experience With 70 Cases

AU - Spaggiari, Lorenzo

AU - Leo, Francesco

AU - Veronesi, Giulia

AU - Solli, Piergiorgio

AU - Galetta, Domenico

AU - Tatani, Brunilda

AU - Petrella, Francesco

AU - Radice, Davide

PY - 2007/1

Y1 - 2007/1

N2 - Background: The oncologic value of superior vena cava (SVC) resection for lung and mediastinal malignancies remains controversial. In this context, we have reviewed our experience in the treatment of locally advanced lung and mediastinal tumor invading the SVC system, analyzing postoperative outcome and long-term oncologic results. Methods: The clinical data of patients who underwent SVC resection were retrospectively analyzed to assess postoperative mortality, and overall and procedure-specific morbidity. Overall survival was calculated for mediastinal and lung tumor groups. Results: From 1998 to 2004, 70 consecutive patients (52 with lung cancer and 18 with mediastinal tumors) underwent SVC system resection. There were 25 replacements (36%) of the SVC system by prosthesis, whereas the remaining underwent partial resection. Major postoperative morbidity and mortality rates in lung cancer patients were 23% and 7.7%, respectively (50% and 5.6% in mediastinal tumors). In the lung cancer group, 5-year survival probability was 31%, and it was affected by mediastinal nodal status (5-year survival in N0-N1 patients 52%, 21% in N2 patients, 0 in N3 patients). Median survival for mediastinal tumors was 49 months. Conclusions: In conclusion, SVC resection may achieve permanent cure in patients who would have been defined as inoperable 10 years ago. In the case of mediastinal tumors, the need for SVC resection alone should not be considered a contraindication for surgery when prosthetic replacement is feasible. In the case of lung tumors, infiltration of SVC can achieve satisfactory long-term results after neoadjuvant chemotherapy, only when pathologic N2 disease is excluded by preoperative mediastinoscopy.

AB - Background: The oncologic value of superior vena cava (SVC) resection for lung and mediastinal malignancies remains controversial. In this context, we have reviewed our experience in the treatment of locally advanced lung and mediastinal tumor invading the SVC system, analyzing postoperative outcome and long-term oncologic results. Methods: The clinical data of patients who underwent SVC resection were retrospectively analyzed to assess postoperative mortality, and overall and procedure-specific morbidity. Overall survival was calculated for mediastinal and lung tumor groups. Results: From 1998 to 2004, 70 consecutive patients (52 with lung cancer and 18 with mediastinal tumors) underwent SVC system resection. There were 25 replacements (36%) of the SVC system by prosthesis, whereas the remaining underwent partial resection. Major postoperative morbidity and mortality rates in lung cancer patients were 23% and 7.7%, respectively (50% and 5.6% in mediastinal tumors). In the lung cancer group, 5-year survival probability was 31%, and it was affected by mediastinal nodal status (5-year survival in N0-N1 patients 52%, 21% in N2 patients, 0 in N3 patients). Median survival for mediastinal tumors was 49 months. Conclusions: In conclusion, SVC resection may achieve permanent cure in patients who would have been defined as inoperable 10 years ago. In the case of mediastinal tumors, the need for SVC resection alone should not be considered a contraindication for surgery when prosthetic replacement is feasible. In the case of lung tumors, infiltration of SVC can achieve satisfactory long-term results after neoadjuvant chemotherapy, only when pathologic N2 disease is excluded by preoperative mediastinoscopy.

UR - http://www.scopus.com/inward/record.url?scp=33845486117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845486117&partnerID=8YFLogxK

U2 - 10.1016/j.athoracsur.2006.07.075

DO - 10.1016/j.athoracsur.2006.07.075

M3 - Article

C2 - 17184668

AN - SCOPUS:33845486117

VL - 83

SP - 223

EP - 230

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 1

ER -